Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia.
Lund B, Åsberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, Söderhäll S, Jónsson ÓG, Lydersen S, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology. Lund B, et al. Among authors: hasle h. Pediatr Blood Cancer. 2011 Apr;56(4):551-9. doi: 10.1002/pbc.22719. Epub 2010 Dec 8. Pediatr Blood Cancer. 2011. PMID: 21298739
Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, Heyman M, Kristinsson J, Nersting J, Nygaard R, Svendsen AL, Vettenranta K, Weinshilboum R; Nordic Society for Paediatric Haematology and Oncology. Schmiegelow K, et al. Among authors: hasle h. Blood. 2009 Jun 11;113(24):6077-84. doi: 10.1182/blood-2008-11-187880. Epub 2009 Feb 17. Blood. 2009. PMID: 19224761 Free PMC article.
Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
Øbro NF, Ryder LP, Madsen HO, Andersen MK, Lausen B, Hasle H, Schmiegelow K, Marquart HV. Øbro NF, et al. Among authors: hasle h. Haematologica. 2012 Jan;97(1):137-41. doi: 10.3324/haematol.2011.051383. Epub 2011 Sep 20. Haematologica. 2012. PMID: 21933850 Free PMC article.
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, Forestier E, Jahnukainen K, Jónsson ÓG, Zeller B, Palle J, Lönnerholm G, Hasle H, Palmqvist L, Ehrencrona H; Nordic Society of Pediatric Hematology and Oncology (NOPHO). Staffas A, et al. Among authors: hasle h. Blood. 2011 Nov 24;118(22):5905-13. doi: 10.1182/blood-2011-05-353185. Epub 2011 Oct 3. Blood. 2011. PMID: 21967978 Free article.
Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study.
Molgaard-Hansen L, Glosli H, Jahnukainen K, Jarfelt M, Jónmundsson GK, Malmros-Svennilson J, Nysom K, Hasle H; Nordic Society of Pediatric Hematology and Oncology. Molgaard-Hansen L, et al. Among authors: hasle h. Pediatr Blood Cancer. 2011 Dec 15;57(7):1222-9. doi: 10.1002/pbc.22931. Epub 2010 Dec 22. Pediatr Blood Cancer. 2011. PMID: 22095929
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.
Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Hasle H, et al. Blood. 2012 Aug 2;120(5):978-84. doi: 10.1182/blood-2012-03-416701. Epub 2012 Jun 22. Blood. 2012. PMID: 22730539 Free article. Clinical Trial.
370 results